Literature DB >> 26758698

Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior.

Maryam Esmaeili1, Mahdi Aghajani1, Roghayeh Abbasalipourkabir2, Amir Amani1,3.   

Abstract

Advantages of lipid nanoparticles for pulmonary applications are possibility of deep lung deposition with prolonged release and low toxicity. This study aimed to evaluate the effects of formulation and processing parameters on particle size of prepared SLNs. Budesonide-loaded solid lipid nanoparticles (BUD-SLNs) were prepared with different values of drug content, ultrasonication amplitude, and homogenization time and the data were modeled using artificial neural networks (ANNs). Optimal conditions for fabrication of small-sized particles of 170-200 nm were found to be low drug content with high-amplitude and high-homogenization time. In vitro aerosolization performance of BUD-SLNs was then compared to that of commercial budesonide which indicated enhancement in fine particle fraction value.

Entities:  

Keywords:  Artificial neural networks; budesonide; size; solid lipid nanoparticles; ultra-sonication

Mesh:

Substances:

Year:  2016        PMID: 26758698     DOI: 10.3109/21691401.2015.1129614

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  3 in total

Review 1.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Acoustically enhanced microfluidic mixer to synthesize highly uniform nanodrugs without the addition of stabilizers.

Authors:  Nguyen Hoai An Le; Hoang Van Phan; Jiaqi Yu; Hak-Kim Chan; Adrian Neild; Tuncay Alan
Journal:  Int J Nanomedicine       Date:  2018-03-08

3.  Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats.

Authors:  Heba F Salem; Ghada Abdelsabour Moubarak; Adel A Ali; Abeer A A Salama; Alaa H Salama
Journal:  J Pharm Sci       Date:  2022-10-10       Impact factor: 3.784

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.